These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22331080)

  • 21. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
    Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
    J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
    Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
    Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
    Bryson PD; Han X; Truong N; Wang P
    Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
    Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
    Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
    Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
    Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a Hsp70L1-Her2(341-456) fusion protein.
    Fu Q; Wu Y; Yan F; Wang N; Wang W; Cao X; Wang Y; Wan T
    Cell Mol Immunol; 2011 Sep; 8(5):424-32. PubMed ID: 21785448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.
    Uherek C; Tonn T; Uherek B; Becker S; Schnierle B; Klingemann HG; Wels W
    Blood; 2002 Aug; 100(4):1265-73. PubMed ID: 12149207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a cancer vaccine: peptides, proteins, and DNA.
    Shiku H; Wang L; Ikuta Y; Okugawa T; Schmitt M; Gu X; Akiyoshi K; Sunamoto J; Nakamura H
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S77-82. PubMed ID: 10950153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.
    Mai TJ; Ma R; Li Z; Bi SC
    Braz J Med Biol Res; 2016 Oct; 49(11):e5620. PubMed ID: 27783810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
    Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
    Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
    Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T
    J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.
    Pruitt SK; Boczkowski D; de Rosa N; Haley NR; Morse MA; Tyler DS; Dannull J; Nair S
    Eur J Immunol; 2011 Dec; 41(12):3553-63. PubMed ID: 22028176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
    Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
    Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.
    Gritzapis AD; Voutsas IF; Baxevanis CN
    Cancer Immunol Immunother; 2012 Mar; 61(3):397-407. PubMed ID: 21928125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.
    Whittington PJ; Radkevich-Brown O; Jacob JB; Jones RF; Weise AM; Wei WZ
    Cancer Immunol Immunother; 2009 May; 58(5):759-67. PubMed ID: 18836716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.